Returning to Boston in April 2026, the 5th LNP Formulation & Process Development Summit is the only industry-led meeting covering end-to-end LNP development. This Summit will be providing the latest scientific content to advance your LNP development for a variety of payloads and therapeutic applications, from mRNA vaccines to next-generation cell and gene therapies. The […]

Welcome to the 3rd GLP-1 Based Therapeutics Summit – the essential industry forum dedicated to solving the critical challenges of GLP-1 combinations, mastering tolerability, drug delivery, and seizing the multi-billion dollar opportunity in non-obesity indications. Driven by unprecedented clinical success, this revolutionary drug class has created multi-billion dollar franchises, but the market is now reaching a critical juncture […]

The SmartLab Exchange USA is an exclusive, invitation-only event designed for senior laboratory, R&D, and digital transformation leaders across pharma, biotech, chemicals, FMCG, and food & beverage. This two-day forum brings together more than 60 decision-makers to tackle one of the industry’s most pressing challenges: how to make lab digitalization work in practice. Every lab […]

As part of SAE’s leading PFS Series, the 2026 conference will once again bring together top experts, industry leaders, and innovators for a three-days of key insights and networking. The conference will feature a comprehensive pre-conference focus day dedicated to advancements in device design, followed by a dynamic two-day main conference featuring keynote plenaries, interactive panel discussions, and specialized topic streams covering the […]

The 5th ADC Analytical Development Summit is the industry’s only dedicated technical forum focused exclusively on solving the analytical challenges unique to antibody–drug conjugate (ADC) development. Designed for analytical, bioanalytical, and CMC leaders, the summit brings together senior experts from across pharma and biotech to advance analytical rigor, deepen product understanding, and enable regulatory-ready ADC […]

Returning for its second year and building on the momentum of an inaugural edition that drew 100+ senior attendees, the 2nd Neuroscience Innovation Partnering & Licensing Summit is engineered to facilitate multiple high-impact, in-person meetings without the distractions of a broader, less-focused setting. Deliberately timed as an exclusive touchpoint for neuroscience business leaders to reconnect between […]

Peptide therapies are rapidly becoming a disruptive modality, led by Merck’s oral PCSK9 inhibitor and Johnson & Johnson’s IL23R, with the hope to develop best-in-class drugs with improved chemistry, formulation and clinical efficacy. To shine a light on the progress of this field, the highly anticipated 3rd Peptide-Based Therapeutics Summit returns to Boston as the industry’s only dedicated platform to turbocharge the next generation […]

The GPCR field is experiencing a renaissance, driven by renewed investment, clinical progress, and next-generation technologies unlocking hundreds of previously untargeted receptors. Furthermore, we’ve recently seen Takeda and Iambic Therapeutics’ $1.7bn partnership to advance AI-driven small molecule programs, and Kainova Therapeutics securing $32m CAD to accelerate immuno-oncology and inflammation therapies, momentum in the GPCR space continues to build. The race is on to […]